$31.17
+2.17 (+7.48%)
QNCX News5 articles
Quince Therapeutics Faces Nasdaq Listing Uncertainty Amid Going Concern Warning
Quince Therapeutics stock trades near $1.15 as the company faces Nasdaq compliance issues, a going concern warning, and a failed Phase 3 trial, with a shareholder vote on a reverse stock split scheduled for June 11.
Reverse Splits Dominate Nasdaq as Compliance Pressures Mount
A surge of reverse stock splits hits Nasdaq-listed companies this week as firms like NextPlat and Cenntro seek to regain compliance, contrasting with recent forward splits from Booking Holdings and Powell Industries.
Quince Therapeutics Surges on Strategic Review Announcement
Quince Therapeutics shares soared nearly 50% in premarket trading after the company hired LifeSci Capital to explore strategic alternatives and restructure liabilities, following a failed Phase 3 trial.
Quince Therapeutics Engages LifeSci for Strategic Review Amid Phase 3 Setback
Quince Therapeutics shares fell 6.6% in premarket trading after hiring LifeSci Capital to explore strategic alternatives and debt restructuring, following a failed Phase 3 trial and board resignations.
Coca-Cola Chairman Quincey Files to Sell $15.7M in Stock After 15% Rally
Coca-Cola Chairman James Quincey filed to sell 200,000 shares valued at $15.7 million, following a 15% stock gain this year. The company recently raised its earnings outlook.